S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 210.5 JPY -0.05% Market Closed
Market Cap: 2T JPY
Have any thoughts about
Shionogi & Co Ltd?
Write Note

Shionogi & Co Ltd
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shionogi & Co Ltd
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
S
Shionogi & Co Ltd
TSE:4507
Other Current Assets
ÂĄ24.7B
CAGR 3-Years
9%
CAGR 5-Years
-3%
CAGR 10-Years
0%
Takeda Pharmaceutical Co Ltd
TSE:4502
Other Current Assets
ÂĄ220.3B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
15%
Daiichi Sankyo Co Ltd
TSE:4568
Other Current Assets
ÂĄ62.8B
CAGR 3-Years
63%
CAGR 5-Years
15%
CAGR 10-Years
15%
Otsuka Holdings Co Ltd
TSE:4578
Other Current Assets
ÂĄ63.7B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Other Current Assets
ÂĄ39.7B
CAGR 3-Years
21%
CAGR 5-Years
21%
CAGR 10-Years
14%
Astellas Pharma Inc
TSE:4503
Other Current Assets
ÂĄ42.6B
CAGR 3-Years
21%
CAGR 5-Years
14%
CAGR 10-Years
13%
No Stocks Found

Shionogi & Co Ltd
Glance View

Market Cap
1.9T JPY
Industry
Pharmaceuticals

In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.

Intrinsic Value
2 171.28 JPY
Overvaluation 2%
Intrinsic Value
Price
S

See Also

What is Shionogi & Co Ltd's Other Current Assets?
Other Current Assets
24.7B JPY

Based on the financial report for Sep 30, 2024, Shionogi & Co Ltd's Other Current Assets amounts to 24.7B JPY.

What is Shionogi & Co Ltd's Other Current Assets growth rate?
Other Current Assets CAGR 10Y
0%

Over the last year, the Other Current Assets growth was -30%. The average annual Other Current Assets growth rates for Shionogi & Co Ltd have been 9% over the past three years , -3% over the past five years .

Back to Top